Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc. today announced that they successfully applied Sutro’s proprietary cell-free expression technology on a commercial scale to manufacture ...

Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, ...

Nuvectis Pharma’s NXP800 shows potential in ovarian cancer but is early stage. Find out why NVCT stock is best suited for ...

A noninvasive method involving brief, localized pulses of magnetic fields could improve chemotherapy effectiveness and reduce ...

Boehringer Ingelheim BioXcellence and Sutro Biopharma (STRO) announced that they successfully applied Sutro’s proprietary cell-free expression ...

While challenges remain, AI is accelerating the process by enabling researchers to identify and design new drug candidates ...

Cell therapies have suffered from hyped-up expectations, clinical setbacks and high costs. But maybe, just maybe, Arovella is ...

Faye Louise, a former model, recovered from cancer after having eight organs removed due to a rare tumor called pseudomyxoma ...

Growing research has shown that even one drink per day can increase the risk of certain cancers such as breast, mouth, and ...

A U.K. woman, who was diagnosed with a rare cancer, recalls having eight organs removed in what she described as 'the mother ...